• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

牙科手术前使用抗生素预防措施可能会降低接受双膦酸盐治疗的多发性骨髓瘤患者颌骨坏死的发生率。

Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates.

作者信息

Montefusco Vittorio, Gay Francesca, Spina Francesco, Miceli Rosalba, Maniezzo Massimo, Teresa Ambrosini Maria, Farina Lucia, Piva Sheila, Palumbo Antonio, Boccadoro Mario, Corradini Paolo

机构信息

Department of Hematology, Allogeneic Bone Marrow Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

出版信息

Leuk Lymphoma. 2008 Nov;49(11):2156-62. doi: 10.1080/10428190802483778.

DOI:10.1080/10428190802483778
PMID:19021059
Abstract

Osteonecrosis of the jaw (ONJ) can be a severe complication of patients with multiple myeloma (MM) treated with bisphosphonates. Dental procedures are a major risk factor for ONJ occurrence. We retrospectively analysed the data of 178 patients with MM to evaluate if antibiotic prophylaxis before dental procedures may prevent ONJ. A correlation between dental procedures, antibiotic prophylaxis, incidence of ONJ and relevant clinical features was performed. Overall nine out of 178 patients developed ONJ (5 year crude cumulative incidence: 7.7%). Only one case of ONJ was not correlated with dental procedures. Seventy-five patients received at least one dental procedure and 43 received antibiotic prophylaxis. Eight cases of ONJ were observed, all in the group of patients without antibiotic prophylaxis. The only variable significantly associated with ONJ was antibiotic prophylaxis (p = 0.012), which had a protective effect. Thus, we speculated that antibiotic prophylaxis may prevent ONJ occurrence after dental procedures.

摘要

颌骨骨坏死(ONJ)可能是接受双膦酸盐治疗的多发性骨髓瘤(MM)患者的一种严重并发症。牙科手术是ONJ发生的主要危险因素。我们回顾性分析了178例MM患者的数据,以评估牙科手术前使用抗生素预防是否可预防ONJ。对牙科手术、抗生素预防、ONJ发生率及相关临床特征之间的相关性进行了分析。178例患者中共有9例发生ONJ(5年粗累积发生率:7.7%)。仅1例ONJ与牙科手术无关。75例患者接受了至少一次牙科手术,43例接受了抗生素预防。观察到8例ONJ,均在未接受抗生素预防的患者组中。与ONJ显著相关的唯一变量是抗生素预防(p = 0.012),其具有保护作用。因此,我们推测抗生素预防可能预防牙科手术后ONJ的发生。

相似文献

1
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates.牙科手术前使用抗生素预防措施可能会降低接受双膦酸盐治疗的多发性骨髓瘤患者颌骨坏死的发生率。
Leuk Lymphoma. 2008 Nov;49(11):2156-62. doi: 10.1080/10428190802483778.
2
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.在接受唑来膦酸治疗的多发性骨髓瘤患者中实施预防措施后,颌骨骨坏死(ONJ)的发生率降低。
Ann Oncol. 2009 Jan;20(1):117-20. doi: 10.1093/annonc/mdn554. Epub 2008 Aug 9.
3
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.接受双膦酸盐治疗的多发性骨髓瘤患者的颌骨骨坏死:唑来膦酸治疗后风险增加的证据。
Haematologica. 2006 Jul;91(7):968-71. Epub 2006 Jun 1.
4
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.在接受双膦酸盐治疗的实体瘤骨转移患者中实施牙科预防措施后,颌骨骨坏死发生率降低。米兰国家癌症研究所的经验。
Ann Oncol. 2009 Jan;20(1):137-45. doi: 10.1093/annonc/mdn526. Epub 2008 Jul 22.
5
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.双膦酸盐治疗后癌症患者颌骨骨坏死:发病率及危险因素
J Clin Oncol. 2005 Dec 1;23(34):8580-7. doi: 10.1200/JCO.2005.02.8670.
6
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.双膦酸盐相关颌骨坏死:35例病例回顾及对多发性骨髓瘤患者中其发生率的评估
Leuk Lymphoma. 2007 Jan;48(1):56-64. doi: 10.1080/10428190600977690.
7
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.唑来膦酸的不同给药方案可降低多发性骨髓瘤患者颌骨坏死的风险。
Leukemia. 2007 Jul;21(7):1545-8. doi: 10.1038/sj.leu.2404682. Epub 2007 Apr 5.
8
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.双膦酸盐相关性颌骨骨坏死癌症患者的危险因素的纵向队列研究。
J Clin Oncol. 2009 Nov 10;27(32):5356-62. doi: 10.1200/JCO.2009.21.9584. Epub 2009 Oct 5.
9
Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.口服双膦酸盐类药物所致颌骨骨坏死:发病率、临床特征、易感因素及治疗结果
Osteoporos Int. 2007 Oct;18(10):1363-70. doi: 10.1007/s00198-007-0384-2. Epub 2007 Jun 28.
10
Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.接受双膦酸盐治疗患者的颌骨骨坏死。附1例多发性骨髓瘤病例报道的文献综述
Folia Med (Plovdiv). 2009 Oct-Dec;51(4):53-7.

引用本文的文献

1
Treatment of myeloma bone disease: When, how often, and for how long?骨髓瘤骨病的治疗:何时、多久进行一次以及持续多长时间?
J Bone Oncol. 2025 Apr 1;52:100680. doi: 10.1016/j.jbo.2025.100680. eCollection 2025 Jun.
2
[Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research].[骨质疏松症——定义、风险评估、诊断、预防与治疗(2024年更新版):奥地利骨与矿物质研究学会指南]
Wien Klin Wochenschr. 2024 Oct;136(Suppl 16):599-668. doi: 10.1007/s00508-024-02441-2. Epub 2024 Oct 2.
3
How we manage medication-related osteonecrosis of the jaw.
我们如何管理药物相关性颌骨坏死。
Eur J Med Res. 2024 Aug 2;29(1):402. doi: 10.1186/s40001-024-01912-6.
4
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.多发性骨髓瘤相关骨病治疗的新进展
Cancers (Basel). 2023 Nov 25;15(23):5585. doi: 10.3390/cancers15235585.
5
Bisphosphonates and Their Connection to Dental Procedures: Exploring Bisphosphonate-Related Osteonecrosis of the Jaws.双膦酸盐及其与牙科手术的关联:探索双膦酸盐相关颌骨坏死
Cancers (Basel). 2023 Nov 10;15(22):5366. doi: 10.3390/cancers15225366.
6
Oral health conditions in patients under antiresorptive therapy are comparable to unexposed during supportive periodontal care.接受抗吸收治疗的患者的口腔健康状况与接受支持性牙周治疗的未暴露患者相当。
Clin Oral Investig. 2023 Nov;27(11):6523-6536. doi: 10.1007/s00784-023-05257-y. Epub 2023 Sep 15.
7
Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake-A Retrospective Cohort Study.抗吸收药物摄入患者预防性拔牙不同抗生素治疗方案的比较——一项回顾性队列研究
Antibiotics (Basel). 2023 Jun 1;12(6):997. doi: 10.3390/antibiotics12060997.
8
MRONJ of the Mandible-From Decortication to a Complex Jaw Reconstruction Using a CAD/CAM-Guided Bilateral Scapula Flap.下颌骨 MRONJ-从骨切开术到使用 CAD/CAM 引导双侧肩胛骨皮瓣的复杂颌骨重建。
Medicina (Kaunas). 2023 Mar 9;59(3):535. doi: 10.3390/medicina59030535.
9
Management of Tooth Extraction in Patients Taking Antiresorptive Drugs: An Evidence Mapping Review and Meta-Analysis.服用抗吸收药物患者的拔牙管理:一项证据图谱综述与荟萃分析
J Clin Med. 2022 Dec 28;12(1):239. doi: 10.3390/jcm12010239.
10
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.颌骨骨坏死与良性及恶性疾病中的抗吸收药物:由 ECTS 组织的批判性回顾。
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1441-1460. doi: 10.1210/clinem/dgab888.